PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism

Makoto Nakagawa, Yasuo Kuwabara, Takayuki Taniwaki, Masayuki Sasaki, Hirofumi Koga, Koichiro Kaneko, Kazutaka Hayashi, Jun-Ichi Kira, Hiroshi Honda

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To clarify the relationship between D2 receptor binding and the cerebral metabolic rate for glucose (CMRGlu) in patients with parkinsonism, we simultaneously measured both of these factors, and then compared the results. Methods: The subjects consisted of 24 patients: 9 with Parkinson's disease (PD), 3 with Juvenile Parkinson's disease (JPD), 9 with multiple system atrophy (MSA), and 3 with progressive supranuclear palsy (PSP). The striatal D2 receptor binding was measured by the C-11 raclopride transient equilibrium method. CMRGlu was investigated by the F-18 fluorodeoxyglucose autoradiographic method. Results: The D2 receptor binding in both the caudate nucleus and putamen showed a positive correlation with the CMRGlu in the PD-JPD group, but the two parameters demonstrated no correlation in the MSA-PSP group. The left/right (L/R) ratio of D2 receptor binding in the putamen showed a positive correlation with that of CMRGlu in the MSA-PSP group, while the two demonsrated no correlation in the PD-JPD group. Conclusion: Our PET study showed striatal D2 receptor binding and the CMRGlu to be closely related in patients with parkinsonism, even though the results obtained using the L/R ratios tended to differ substantially from those obtained using absolute values. The reason for this difference is not clear, but this finding may reflect the pathophysiology of these disease entities.

Original languageEnglish
Pages (from-to)267-275
Number of pages9
JournalAnnals of Nuclear Medicine
Volume19
Issue number4
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Parkinsonian Disorders
Multiple System Atrophy
Glucose
Progressive Supranuclear Palsy
Corpus Striatum
Putamen
Parkinson Disease
Raclopride
Caudate Nucleus
Fluorodeoxyglucose F18
glucose receptor

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. / Nakagawa, Makoto; Kuwabara, Yasuo; Taniwaki, Takayuki; Sasaki, Masayuki; Koga, Hirofumi; Kaneko, Koichiro; Hayashi, Kazutaka; Kira, Jun-Ichi; Honda, Hiroshi.

In: Annals of Nuclear Medicine, Vol. 19, No. 4, 01.01.2005, p. 267-275.

Research output: Contribution to journalArticle

Nakagawa, Makoto ; Kuwabara, Yasuo ; Taniwaki, Takayuki ; Sasaki, Masayuki ; Koga, Hirofumi ; Kaneko, Koichiro ; Hayashi, Kazutaka ; Kira, Jun-Ichi ; Honda, Hiroshi. / PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. In: Annals of Nuclear Medicine. 2005 ; Vol. 19, No. 4. pp. 267-275.
@article{bb011d474c2c416f88a121d6e503c15e,
title = "PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism",
abstract = "Objective: To clarify the relationship between D2 receptor binding and the cerebral metabolic rate for glucose (CMRGlu) in patients with parkinsonism, we simultaneously measured both of these factors, and then compared the results. Methods: The subjects consisted of 24 patients: 9 with Parkinson's disease (PD), 3 with Juvenile Parkinson's disease (JPD), 9 with multiple system atrophy (MSA), and 3 with progressive supranuclear palsy (PSP). The striatal D2 receptor binding was measured by the C-11 raclopride transient equilibrium method. CMRGlu was investigated by the F-18 fluorodeoxyglucose autoradiographic method. Results: The D2 receptor binding in both the caudate nucleus and putamen showed a positive correlation with the CMRGlu in the PD-JPD group, but the two parameters demonstrated no correlation in the MSA-PSP group. The left/right (L/R) ratio of D2 receptor binding in the putamen showed a positive correlation with that of CMRGlu in the MSA-PSP group, while the two demonsrated no correlation in the PD-JPD group. Conclusion: Our PET study showed striatal D2 receptor binding and the CMRGlu to be closely related in patients with parkinsonism, even though the results obtained using the L/R ratios tended to differ substantially from those obtained using absolute values. The reason for this difference is not clear, but this finding may reflect the pathophysiology of these disease entities.",
author = "Makoto Nakagawa and Yasuo Kuwabara and Takayuki Taniwaki and Masayuki Sasaki and Hirofumi Koga and Koichiro Kaneko and Kazutaka Hayashi and Jun-Ichi Kira and Hiroshi Honda",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/BF02984618",
language = "English",
volume = "19",
pages = "267--275",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism

AU - Nakagawa, Makoto

AU - Kuwabara, Yasuo

AU - Taniwaki, Takayuki

AU - Sasaki, Masayuki

AU - Koga, Hirofumi

AU - Kaneko, Koichiro

AU - Hayashi, Kazutaka

AU - Kira, Jun-Ichi

AU - Honda, Hiroshi

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: To clarify the relationship between D2 receptor binding and the cerebral metabolic rate for glucose (CMRGlu) in patients with parkinsonism, we simultaneously measured both of these factors, and then compared the results. Methods: The subjects consisted of 24 patients: 9 with Parkinson's disease (PD), 3 with Juvenile Parkinson's disease (JPD), 9 with multiple system atrophy (MSA), and 3 with progressive supranuclear palsy (PSP). The striatal D2 receptor binding was measured by the C-11 raclopride transient equilibrium method. CMRGlu was investigated by the F-18 fluorodeoxyglucose autoradiographic method. Results: The D2 receptor binding in both the caudate nucleus and putamen showed a positive correlation with the CMRGlu in the PD-JPD group, but the two parameters demonstrated no correlation in the MSA-PSP group. The left/right (L/R) ratio of D2 receptor binding in the putamen showed a positive correlation with that of CMRGlu in the MSA-PSP group, while the two demonsrated no correlation in the PD-JPD group. Conclusion: Our PET study showed striatal D2 receptor binding and the CMRGlu to be closely related in patients with parkinsonism, even though the results obtained using the L/R ratios tended to differ substantially from those obtained using absolute values. The reason for this difference is not clear, but this finding may reflect the pathophysiology of these disease entities.

AB - Objective: To clarify the relationship between D2 receptor binding and the cerebral metabolic rate for glucose (CMRGlu) in patients with parkinsonism, we simultaneously measured both of these factors, and then compared the results. Methods: The subjects consisted of 24 patients: 9 with Parkinson's disease (PD), 3 with Juvenile Parkinson's disease (JPD), 9 with multiple system atrophy (MSA), and 3 with progressive supranuclear palsy (PSP). The striatal D2 receptor binding was measured by the C-11 raclopride transient equilibrium method. CMRGlu was investigated by the F-18 fluorodeoxyglucose autoradiographic method. Results: The D2 receptor binding in both the caudate nucleus and putamen showed a positive correlation with the CMRGlu in the PD-JPD group, but the two parameters demonstrated no correlation in the MSA-PSP group. The left/right (L/R) ratio of D2 receptor binding in the putamen showed a positive correlation with that of CMRGlu in the MSA-PSP group, while the two demonsrated no correlation in the PD-JPD group. Conclusion: Our PET study showed striatal D2 receptor binding and the CMRGlu to be closely related in patients with parkinsonism, even though the results obtained using the L/R ratios tended to differ substantially from those obtained using absolute values. The reason for this difference is not clear, but this finding may reflect the pathophysiology of these disease entities.

UR - http://www.scopus.com/inward/record.url?scp=23344435367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344435367&partnerID=8YFLogxK

U2 - 10.1007/BF02984618

DO - 10.1007/BF02984618

M3 - Article

C2 - 16097635

AN - SCOPUS:23344435367

VL - 19

SP - 267

EP - 275

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 4

ER -